Revenue Analysis - LGND
Comprehensive quarterly and annual revenue breakdown by product lines and geographic regions to identify growth drivers and market opportunities.
LGND Corporation
Revenue by Product Line
Latest quarterly revenue breakdown by product segments
Quarterly Product Revenue
Product Revenue Details
Detailed breakdown of revenue by product line
Contract Revenue
0.0% of total revenue
$66.7M
Royalty
0.0% of total revenue
$50.5M
Intangible Royalty Assets
0.0% of total revenue
$40.7M
Financial Royalty Assets
0.0% of total revenue
$9.8M
Material Sales, Captisol
0.0% of total revenue
$7.8M
Historical Revenue Data
Quarterly product revenue breakdown over time (Last 6 records)
| Date | Contract Revenue | Evomela | Financial Royalty Assets | Intangible Royalty Assets | Kyprolis | Material Sales, Captisol | Royalty | Royalty, Other | Rylaze | Teriparatide Injection |
|---|---|---|---|---|---|---|---|---|---|---|
| 12/31/2025 | $66.7M | $0 | $9.8M | $40.7M | $0 | $7.8M | $50.5M | $0 | $0 | $0 |
| 9/30/2025 | $131.0K | $1.9M | $6.4M | $40.2M | $11.6M | $10.7M | $46.6M | $0 | $3.6M | $2.6M |
| 6/30/2025 | $0 | $1.5M | $6.3M | $30.1M | $8.8M | $8.3M | $36.4M | $0 | $2.9M | $2.3M |
| 3/31/2025 | $0 | $2.0M | $5.9M | $21.6M | $4.7M | $13.5M | $27.5M | $0 | $3.1M | $1.2M |
| 12/31/2024 | $0 | $0 | $8.3M | $68.8M | $0 | $24.6M | $77.1M | $6.7M | $0 | $0 |
| 9/30/2024 | $0 | $1.7M | $5.2M | $26.6M | $11.6M | $6.3M | $31.7M | $2.3M | $3.9M | $2.4M |
Revenue Trend Analysis
Analysis of major growing and declining segments based on recent revenue data
Product Segments
Growing Segments
Declining Segments
Earnings Reports
Want to see how LGND's earnings relate to revenue? View quarterly earnings results, EPS history, and earnings surprises to understand the company's profitability.
View Earnings Reports